At a $399M market cap with no P/E or Forward P/E, a deeply negative EPS of -1.6, and an Altman Z-Score of -7.6, this is not a growth story—it is a balance sheet stress case priced like an option on survival. The absence of earnings visibility combined with Sales Growth Next Year of -$3.86 signals contraction, not inflection. Price/Book at 0.8 superficially screens as deep value, but with ROIC at -31.40% and Operating Margin at -61.50%, the company is destroying capital, not compounding it. The market is not mispricing safety here; it is pricing distress, and the financial profile justifies that skepticism.
